Researchers Use Emerging Ovarian Cancer Biomarker to Develop New Blood Test for Ovarian Cancer

Researchers at the University of Manchester have developed a new blood test that can help diagnose ovarian cancer faster and more accurately in women, particularly those under the age of 50, using a newer ovarian cancer biomarker.

The blood test can be administered by general practitioners/physicians.

The test includes the use of the emerging ovarian cancer biomarker, human epididymis protein 4 (HE4). The US Food and Drug Administration (FDA) approved the use of HE4 for monitoring remission in patients with epithelial ovarian cancer, and also as a complementary marker that can be used in conjunction with the more commonly used cancer antigen-125 (CA-125) biomarker.